Jyonouchi H, Voss R M, Good R A
Department of Pediatrics, University of South Florida/All Children's Hospital, St. Petersburg 33701.
Clin Immunol Immunopathol. 1991 Jun;59(3):388-97. doi: 10.1016/0090-1229(91)90034-8.
In vivo effects of NZB serum factor (NZB-SF), which enhances the maturation of B precursor cells in vitro, were examined. Immunoaffinity-purified NZB-SF from young NZB mice was injected into B6 mice intraperitoneally twice weekly, five times total (5 micrograms/dose/mouse). Control mice were given 0.01% albumin. Then the B lineage cell populations defined phenotypically (sIg+ cells, B220+ cells, and AA4.1+ cells) or the numbers of colony-forming B lineage cells were examined. NZB-SF-treated B6 mice exhibited a decrease in the percentage of B precursor cells in marrow, even though the percentage of sIg+ cells in marrow or spleen did not differ from controls. In contrast, the frequency of colony-forming B cells in marrow and spleen, especially sIg- colony-forming B cells in marrow, increased significantly in NZB-SF-treated mice as compared to controls. In addition, monoclonal antibody (mAb) against NZB-SF was injected weekly for 9 weeks into NZB mice beginning at 7 weeks of age. mAb vs NZB-SF at a dose of 5 micrograms per mouse per injection, as stated above, prevented the decline of sIg- colony-forming B lineage cells which usually occurred in the adult NZB mice (greater than 16 weeks). This treatment also prevented, in part, the decline of the B220+ cell population which normally occurs in the marrow with increasing age. Thus NZB-SF impressively influences the composition of B lineage cell populations in normal B6 mice and may account for abnormal changes of B lineage cell populations observed in NZB mice.
研究了NZB血清因子（NZB-SF）在体内的作用，该因子在体外可促进B前体细胞的成熟。从年轻NZB小鼠中通过免疫亲和纯化得到的NZB-SF，以每周两次的频率腹腔注射到B6小鼠体内，共注射五次（每只小鼠每次剂量为5微克）。对照小鼠注射0.01%的白蛋白。然后检查通过表型定义的B谱系细胞群体（表面免疫球蛋白阳性细胞、B220阳性细胞和AA4.1阳性细胞）或集落形成B谱系细胞的数量。接受NZB-SF治疗的B6小鼠骨髓中B前体细胞的百分比降低，尽管骨髓或脾脏中表面免疫球蛋白阳性细胞的百分比与对照无差异。相比之下，与对照相比，接受NZB-SF治疗的小鼠骨髓和脾脏中集落形成B细胞的频率显著增加，尤其是骨髓中表面免疫球蛋白阴性的集落形成B细胞。此外，从7周龄开始，每周给NZB小鼠注射抗NZB-SF单克隆抗体（mAb），持续9周。如上所述，每只小鼠每次注射5微克的抗NZB-SF mAb可防止成年NZB小鼠（大于16周）中通常出现的表面免疫球蛋白阴性集落形成B谱系细胞的减少。这种治疗也部分防止了随着年龄增长骨髓中正常出现的B220阳性细胞群体的减少。因此，NZB-SF对正常B6小鼠中B谱系细胞群体的组成有显著影响，可能是NZB小鼠中观察到的B谱系细胞群体异常变化的原因。
